S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.

Cyril Sobolewski, Daniel Abegg, Flavien Berthou, Dobrochna Dolicka, Nicolas Calo, Christine Sempoux, Margot Fournier, Christine Maeder, Anne-Sophie Ay, Pierre-Alain Clavien, Bostjan Humar, Jean-François Dufour, Alexander Adibekian & Michelangelo Foti
OBJECTIVE Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations....
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.